IC7: a gp130 receptor ligand to treat type 2 diabetes

IC7：治疗 2 型糖尿病的 gp130 受体配体

• 批准号: nhmrc : 1042465
• 负责人: Prof Mark Febbraio
• 金额: $ 39.93万
• 依托单位: Baker IDI Heart and Diabetes Institute
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/ic7-gp130-receptor-2-diabetes/111470
• 关键词: IC7; gp130; receptor; ligand; treat

Over the past decade work from our group has identified that a group of proteins, termed gp130 receptor cytokines, can lead to improvements in both causes and symptoms of type 2 diabetes in both animals and humans. Unfortunately, due to side effects, clinical trial using analogues of these proteins have failed. We believe we know why this is the case and we now have developed new, improved peptides that should overcome these side effects. We hope that we have created a novel drug that will help treat type 2 diabetes.

在过去的十年里，我们小组的工作已经确定了一组蛋白质，称为gp130受体细胞因子，可以改善动物和人类2型糖尿病的病因和症状。不幸的是，由于副作用，使用这些蛋白质类似物的临床试验失败了。我们相信我们知道为什么会这样，我们现在已经开发出新的，改进的肽，应该克服这些副作用。我们希望我们已经发明了一种有助于治疗2型糖尿病的新药。